Lexicon Pharmaceuticals (NASDAQ:LXRX) stock is soaring 5.05% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results, which surpassed analysts' expectations. The biopharmaceutical company reported a narrower loss and a substantial increase in revenue, demonstrating significant progress in its operations.
For Q3 2025, Lexicon posted a loss of $0.04 per share, beating the analyst consensus estimate of $0.07 per share. This represents a notable improvement from the $0.18 per share loss reported in the same quarter last year. The company's revenue skyrocketed to $14.18 million, a 710.4% increase from the previous year and far exceeding the analyst expectations of $4.65 million. The surge in revenue was primarily attributed to licensing agreements, particularly with Novo Nordisk.
Investors are also encouraged by Lexicon's pipeline progress, including the completion of IND-enabling studies for LX9851 in obesity and the ongoing SONATA-HCM Phase 3 study of sotagliflozin. Additionally, the company is preparing for an FDA End-of-Phase 2 meeting for pilavapadin in diabetic peripheral neuropathic pain by year-end, further bolstering confidence in its development programs. With $145 million in cash and investments as of September 30, Lexicon appears well-positioned to advance its strategic initiatives in the coming year.
Comments